Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2026 | Overweight | Cantor Fitzgerald | |
| 3/2/2026 | $32.00 | Overweight | Morgan Stanley |
| 3/2/2026 | $29.00 | Overweight | Analyst |
| 3/2/2026 | $26.00 | Outperform | Mizuho |
| 3/2/2026 | $34.00 | Buy | BofA Securities |
| 2/26/2026 | $7.00 | Underperform | Wedbush |
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
Cantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight
Morgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00
Analyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00
SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
SCHEDULE 13D - Eikon Therapeutics, Inc. (0001861123) (Subject)
SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)